{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:19:24Z","timestamp":1784179164233,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The study evaluated clinical efficacy of intensity modulated radiation therapy (IMRT) in treating patients with thyroid-associated ophthalmopathy (TAO) and defined predictive factors that associated with treatment response. A total of 178 TAO patients were treated with retro-orbital IMRT with radiation dose of 20\u2009Gy in 10 fractions. The immediate and long-term treatment response and complications were evaluated. Besides, logistic-regression analysis was conducted to identify possible predictive factors. TAO symptom score significantly fell from the initiation to 6-month post-treatment (P\u2009&lt;\u20090.001). 134 patients (73.2%) had mild to significant response to IMRT, and 172 patients (96.6%) achieved stabilization of TAO without future progression. Current smoker (OR 2.88, 95% CI 1.32\u20136.29; P\u2009=\u20090.008) and symptom duration longer than 18 months (OR 3.33, 95% CI 1.24\u20138.93; P\u2009=\u20090.017) were identified as independent predictive factors for non-response of TAO to retro-orbital IMRT. Immediate complications were slight and self-limited, and long-term complications mainly included chronic xerophthalmias in12 patients (6.74%) and cataract formation in 4 patients (2.25%). The study suggested that IMRT was a viable option for treating TAO patients, with a satisfactory symptom control ability and acceptable post-treatment complications.<\/jats:p>","DOI":"10.1038\/s41598-017-17893-y","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T12:50:23Z","timestamp":1512651023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The efficacy of intensity modulated radiation therapy in treating thyroid-associated ophthalmopathy and predictive factors for treatment response"],"prefix":"10.1038","volume":"7","author":[{"given":"Yong-Jiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"17893_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1530\/eje.0.1460457","volume":"146","author":"L Bartalena","year":"2002","unstructured":"Bartalena, L., Marcocci, C. & Pinchera, A. Graves\u2019 ophthalmopathy: a preventable disease? Eur J Endocrinol. \n                           146, 457\u201361 (2002).","journal-title":"Eur J Endocrinol."},{"key":"17893_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","volume":"5","author":"WM Wiersinga","year":"2017","unstructured":"Wiersinga, W. M. Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy. Lancet Diabetes Endocrinol. \n                           5, 134\u201342, https:\/\/doi.org\/10.1016\/S2213-8587(16)30046-8 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"17893_CR3","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJM199206253262610","volume":"326","author":"RD Utiger","year":"1992","unstructured":"Utiger, R. D. Pathogenesis of Graves\u2019 ophthalmopathy. N Engl J Med. \n                           326, 1772\u20133, https:\/\/doi.org\/10.1056\/NEJM199206253262610 (1992).","journal-title":"N Engl J Med."},{"key":"17893_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1210\/edrv.21.2.0393","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena, L., Pinchera, A. & Marcocci, C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev. \n                           21, 168\u201399, https:\/\/doi.org\/10.1210\/edrv.21.2.0393 (2000).","journal-title":"Endocr Rev."},{"key":"17893_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.14.6.747","volume":"14","author":"HB Burch","year":"1993","unstructured":"Burch, H. B. & Wartofsky, L. Graves Ophthalmopathy - Current Concepts Regarding Pathogenesis and Management. Endocr Rev. \n                           14, 747\u201393, https:\/\/doi.org\/10.1210\/er.14.6.747 (1993).","journal-title":"Endocr Rev."},{"key":"17893_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijrobp.2010.08.053","volume":"82","author":"C Matthiesen","year":"2012","unstructured":"Matthiesen, C. et al. The efficacy of radiation therapy in the treatment of Graves\u2019 orbitopathy. Int J Radiat Oncol Biol Phys. \n                           82, 117\u201323, https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.053 (2012).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","volume":"342","author":"MF Prummel","year":"1993","unstructured":"Prummel, M. F. et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves\u2019 ophthalmopathy. Lancet. \n                           342, 949\u201354 (1993).","journal-title":"Lancet."},{"key":"17893_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits, M. P. et al. Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet. \n                           355, 1505\u20139, https:\/\/doi.org\/10.1016\/S0140-6736(00)02165-6 (2000).","journal-title":"Lancet."},{"key":"17893_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/105072502753600223","volume":"12","author":"L Bartalena","year":"2002","unstructured":"Bartalena, L. et al. Orbital radiotherapy for Graves\u2019 ophthalmopathy. Thyroid. \n                           12, 245\u201350, https:\/\/doi.org\/10.1089\/105072502753600223 (2002).","journal-title":"Thyroid."},{"key":"17893_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0002-9394(02)01970-0","volume":"135","author":"K Ohtsuka","year":"2003","unstructured":"Ohtsuka, K., Sato, A., Kawaguchi, S., Hashimoto, M. & Suzuki, Y. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves\u2019 ophthalmopathy. Am J Ophthalmol. \n                           135, 285\u201390 (2003).","journal-title":"Am J Ophthalmol."},{"key":"17893_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijrobp.2017.01.006","volume":"98","author":"EL Pollom","year":"2017","unstructured":"Pollom, E. L. et al. The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. \n                           98, 177\u201385, https:\/\/doi.org\/10.1016\/j.ijrobp.2017.01.006 (2017).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0360-3016(00)01441-3","volume":"49","author":"KS Chao","year":"2001","unstructured":"Chao, K. S. et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. \n                           49, 907\u201316 (2001).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","volume":"12","author":"CM Nutting","year":"2011","unstructured":"Nutting, C. M. et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. \n                           12, 127\u201336, https:\/\/doi.org\/10.1016\/S1470-2045(10)70290-4 (2011).","journal-title":"Lancet Oncol."},{"key":"17893_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-199","volume":"7","author":"VH Lee","year":"2012","unstructured":"Lee, V. H. et al. Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves\u2019 ophthalmopathy treated with retro-orbital irradiation. Radiat Oncol. \n                           7, 199, https:\/\/doi.org\/10.1186\/1748-717X-7-199 (2012).","journal-title":"Radiat Oncol."},{"key":"17893_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0002-9394(77)90140-4","volume":"83","author":"SC Werner","year":"1977","unstructured":"Werner, S. C. Modification of the classification of the eye changes of Graves\u2019 disease. Am J Ophthalmol. \n                           83, 725\u20137 (1977).","journal-title":"Am J Ophthalmol."},{"key":"17893_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/thy.1992.2.85","volume":"2","author":"BR Frueh","year":"1992","unstructured":"Frueh, B. R. Why the NOSPECS classification of Graves\u2019 eye disease should be abandoned, with suggestions for the characterization of this disease. Thyroid. \n                           2, 85\u20138, https:\/\/doi.org\/10.1089\/thy.1992.2.85 (1992).","journal-title":"Thyroid."},{"key":"17893_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-95","volume":"7","author":"RS Prabhu","year":"2012","unstructured":"Prabhu, R. S. et al. Clinical outcomes of radiotherapy as initial local therapy for Graves\u2019 ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery. Radiat Oncol. \n                           7, 95, https:\/\/doi.org\/10.1186\/1748-717x-7-95 (2012).","journal-title":"Radiat Oncol."},{"key":"17893_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0360-3016(01)01699-6","volume":"51","author":"SD Marquez","year":"2001","unstructured":"Marquez, S. D. et al. Long-term results of irradiation for patients with progressive Graves\u2019 ophthalmopathy. Int J Radiat Oncol Biol Phys. \n                           51, 766\u201374 (2001).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-46","volume":"6","author":"M Abboud","year":"2011","unstructured":"Abboud, M., Arabi, A., Salti, I. & Geara, F. Outcome of thyroid associated ophthalmopathy treated by radiation therapy. Radiat Oncol. \n                           6, 46, https:\/\/doi.org\/10.1186\/1748-717X-6-46 (2011).","journal-title":"Radiat Oncol."},{"key":"17893_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2010.0218","volume":"21","author":"NI Regensburg","year":"2011","unstructured":"Regensburg, N. I., Wiersinga, W. M., Berendschot, T. T., Saeed, P. & Mourits, M. P. Effect of smoking on orbital fat and muscle volume in Graves\u2019 orbitopathy. Thyroid. \n                           21, 177\u201381, https:\/\/doi.org\/10.1089\/thy.2010.0218 (2011).","journal-title":"Thyroid."},{"key":"17893_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF03345276","volume":"27","author":"L Hegedus","year":"2004","unstructured":"Hegedus, L., Brix, T. H. & Vestergaard, P. Relationship between cigarette smoking and Graves\u2019 ophthalmopathy. J Endocrinol Invest. \n                           27, 265\u201371 (2004).","journal-title":"J Endocrinol Invest."},{"key":"17893_CR22","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/bjophthalmol-2014-306463","volume":"99","author":"LJ Xing","year":"2015","unstructured":"Xing, L. J. et al. Smoking was associated with poor response to intravenous steroids therapy in Graves\u2019 ophthalmopathy. Brit J Ophthalmol. \n                           99, 1686\u201391, https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306463 (2015).","journal-title":"Brit J Ophthalmol."},{"key":"17893_CR23","doi-asserted-by":"publisher","first-page":"4676289","DOI":"10.1155\/2016\/4676289","volume":"2016","author":"HC Kau","year":"2016","unstructured":"Kau, H. C., Wu, S. B., Tsai, C. C., Liu, C. J. & Wei, Y. H. Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves\u2019 Ophthalmopathy. Oxid Med Cell Longev. \n                           2016, 4676289, https:\/\/doi.org\/10.1155\/2016\/4676289 (2016).","journal-title":"Oxid Med Cell Longev."},{"key":"17893_CR24","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1210\/jc.2016-1279","volume":"101","author":"GE Gortz","year":"2016","unstructured":"Gortz, G. E. et al. Hypoxia-Dependent HIF-1 Activation Impacts on Tissue Remodeling in Graves\u2019 Ophthalmopathy-Implications for Smoking. J Clin Endocrinol Metab. \n                           101, 4834\u201342, https:\/\/doi.org\/10.1210\/jc.2016-1279 (2016).","journal-title":"J Clin Endocrinol Metab."},{"key":"17893_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0360-3016(00)00668-4","volume":"48","author":"K Tsujino","year":"2000","unstructured":"Tsujino, K. et al. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves\u2019 ophthalmopathy. Int J Radiat Oncol Biol Phys. \n                           48, 857\u201364 (2000).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","volume":"56","author":"L Bartalena","year":"1983","unstructured":"Bartalena, L. et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. \n                           56, 1139\u201344, https:\/\/doi.org\/10.1210\/jcem-56-6-1139 (1983).","journal-title":"J Clin Endocrinol Metab."},{"key":"17893_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/BF03347943","volume":"14","author":"C Marcocci","year":"1991","unstructured":"Marcocci, C. et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. \n                           14, 853\u201360, https:\/\/doi.org\/10.1007\/BF03347943 (1991).","journal-title":"J Endocrinol Invest."},{"key":"17893_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami, B. et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. \n                           21, 109\u201322 (1991).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR29","first-page":"325","volume":"106","author":"JL Kinyoun","year":"2008","unstructured":"Kinyoun, J. L. Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis). Trans Am Ophthalmol Soc. \n                           106, 325\u201335 (2008).","journal-title":"Trans Am Ophthalmol Soc."},{"key":"17893_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0360-3016(99)00057-7","volume":"44","author":"A Takeda","year":"1999","unstructured":"Takeda, A. et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys. \n                           44, 599\u2013605 (1999).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17893_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0167-8140(99)00118-8","volume":"53","author":"JJ Broerse","year":"1999","unstructured":"Broerse, J. J. et al. Assessment of a carcinogenic risk for treatment of Graves\u2019 ophthalmopathy in dependence on age and irradiation geometry. Radiother Oncol. \n                           53, 205\u20138 (1999).","journal-title":"Radiother Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17893-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17893-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17893-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:18:15Z","timestamp":1671812295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17893-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["17893"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17893-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,13]]},"assertion":[{"value":"11 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17533"}}